TLSI 4.07 Stock Price TriSalus Life Sciences, Inc.
Range: | 3.33-10.42 | Vol Avg: | 44889 | Last Div: | 0 | Changes: | 0.1 |
Beta: | 0.5 | Cap: | 0.14B | Currency: | USD | Exchange: | NASDAQ |
Sector: | Healthcare | IPO: | Mon Feb 08 2021 | Empoloyees: | 107 |
CUSIP: | 89680M101 | CIK: | 0001826667 | ISIN: | US89680M1018 | Country: | US |
CEO: | Ms. Mary T. Szela B.S.N., M.B.A. | Website: | https://trisaluslifesci.com |
TriSalus Life Sciences, Inc., an immunotherapy company that develops and commercializes immunotherapies for the treatment of liver and pancreatic tumors. The company offers the TriNav Infusion System for hepatic arterial infusion of liver tumors; and the Pancreatic Retrograde Venous Infusion System for pancreatic tumors. It also develops SD-101, an investigational immunotherapeutic with pressure-enabled drug delivery technology for hepatocellular carcinoma, intrahepatic cholangiocarcinoma, uveal melanoma with liver metastases, pancreatic ductal adenocarcinoma with liver metastases, colorectal cancer with liver metastases, and primary pancreatic cancers. The company is based in Westminster, Colorado.
The content provided on this site is for informational purposes only and does not constitute financial, investment, or professional advice. We are not registered investment advisors or financial planners, and we do not provide recommendations or advice on buying, selling, or holding any particular stocks or securities. Any investment decisions should be made based on your own research and consultation with a qualified financial professional. We are not responsible for any financial loss or damages incurred from reliance on the information provided on this site. Please invest responsibly and seek professional advice when needed.